Literature DB >> 31792055

High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.

Mary Migliorini1, Shih-Hon Li2, Anqi Zhou3, Cory D Emal4, Daniel A Lawrence5, Dudley K Strickland6.   

Abstract

It is well-established that complexes of plasminogen-activator inhibitor 1 (PAI-1) with its target enzymes bind tightly to low-density lipoprotein (LDL) receptor-related protein 1 (LRP1), but the molecular details of this interaction are not well-defined. Furthermore, considerable controversy exists in the literature regarding the nature of the interaction of free PAI-1 with LRP1. In this study, we examined the binding of free PAI-1 and complexes of PAI-1 with low-molecular-weight urokinase-type plasminogen activator to LRP1. Our results confirmed that uPA:PAI-1 complexes bind LRP1 with ∼100-fold increased affinity over PAI-1 alone. Chemical modification of PAI-1 confirmed an essential requirement of lysine residues in PAI-1 for the interactions of both PAI-1 and uPA:PAI-1 complexes with LRP1. Results of surface plasmon resonance measurements supported a bivalent binding model in which multiple sites on PAI-1 and uPA:PAI-1 complexes interact with complementary sites on LRP1. An ionic-strength dependence of binding suggested the critical involvement of two charged residues for the interaction of PAI-1 with LRP1 and three charged residues for the interaction of uPA:PAI-1 complexes with LRP1. An enhanced affinity resulting from the interaction of three regions of the uPA:PAI-1 complex with LDLa repeats on LRP1 provided an explanation for the increased affinity of uPA:PAI-1 complexes for LRP1. Mutational analysis revealed an overlap between LRP1 binding and binding of a small-molecule inhibitor of PAI-1, CDE-096, confirming an important role for Lys-207 in the interaction of PAI-1 with LRP1 and of the orientations of Lys-207, -88, and -80 for the interaction of uPA:PAI-1 complexes with LRP1.
© 2020 Migliorini et al.

Entities:  

Keywords:  LRP1; PAI-1; fibrinolysis; ligand recognition; lipoprotein receptor-related protein (LRP); plasminogen activation; serpin; site-directed mutagenesis; surface plasmon resonance (SPR)

Mesh:

Substances:

Year:  2019        PMID: 31792055      PMCID: PMC6952620          DOI: 10.1074/jbc.RA119.010449

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Development of inhibitors of plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Daniel A Lawrence
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

2.  VADAR: a web server for quantitative evaluation of protein structure quality.

Authors:  Leigh Willard; Anuj Ranjan; Haiyan Zhang; Hassan Monzavi; Robert F Boyko; Brian D Sykes; David S Wishart
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

3.  Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

4.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

5.  Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins.

Authors:  R W Mahley; T L Innerarity; R E Pitas; K H Weisgraber; J H Brown; E Gross
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

6.  The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.

Authors:  A M Sharp; P E Stein; N S Pannu; R W Carrell; M B Berkenpas; D Ginsburg; D A Lawrence; R J Read
Journal:  Structure       Date:  1999-02-15       Impact factor: 5.006

7.  Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein.

Authors:  S Stefansson; S Muhammad; X F Cheng; F D Battey; D K Strickland; D A Lawrence
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

8.  Structure of the minimal interface between ApoE and LRP.

Authors:  Miklos Guttman; J Helena Prieto; Tracy M Handel; Peter J Domaille; Elizabeth A Komives
Journal:  J Mol Biol       Date:  2010-03-19       Impact factor: 5.469

9.  Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.

Authors:  Natalia V Gorlatova; Hassan Elokdah; Kristi Fan; David L Crandall; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2003-02-26       Impact factor: 5.157

10.  A proximal pair of positive charges provides the dominant ligand-binding contribution to complement-like domains from the LRP (low-density lipoprotein receptor-related protein).

Authors:  Peter G W Gettins; Klavs Dolmer
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

View more
  8 in total

1.  α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.

Authors:  Zixuan Wang; Stefano Martellucci; Alicia Van Enoo; Dana Austin; Cohava Gelber; Wendy M Campana
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

2.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

3.  Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism.

Authors:  Joanna M Cooper; Aurelien Lathuiliere; Mary Migliorini; Allison L Arai; Mashhood M Wani; Simon Dujardin; Selen C Muratoglu; Bradley T Hyman; Dudley K Strickland
Journal:  J Biol Chem       Date:  2021-04-27       Impact factor: 5.157

4.  Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling.

Authors:  Sonali Munshaw; Susann Bruche; Andia N Redpath; Alisha Jones; Jyoti Patel; Karina N Dubé; Regent Lee; Svenja S Hester; Rachel Davies; Giles Neal; Ashok Handa; Michael Sattler; Roman Fischer; Keith M Channon; Nicola Smart
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

5.  High-Affinity Binding of LDL Receptor-Related Protein 1 to Matrix Metalloprotease 1 Requires Protease:Inhibitor Complex Formation.

Authors:  Allison L Arai; Mary Migliorini; Dianaly T Au; Elizabeth Hahn-Dantona; David Peeney; William G Stetler-Stevenson; Selen C Muratoglu; Dudley K Strickland
Journal:  Biochemistry       Date:  2020-08-06       Impact factor: 3.162

6.  Role of PAI-1 in hepatic steatosis and dyslipidemia.

Authors:  Joshua A Levine; Carlota Oleaga; Mesut Eren; Ansel P Amaral; Meng Shang; Elizabeth Lux; Sadiya S Khan; Sanjiv J Shah; Yasuhiro Omura; Nathalie Pamir; Joshua Hay; Grant Barish; Toshio Miyata; Hagai Tavori; Sergio Fazio; Douglas E Vaughan
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

7.  A soluble derivative of PrPC activates cell-signaling and regulates cell physiology through LRP1 and the NMDA receptor.

Authors:  Elisabetta Mantuano; Pardis Azmoon; Michael A Banki; Michael S Lam; Christina J Sigurdson; Steven L Gonias
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

8.  Complement C1q Interacts With LRP1 Clusters II and IV Through a Site Close but Different From the Binding Site of Its C1r and C1s-Associated Proteases.

Authors:  Guillaume Fouët; Evelyne Gout; Catherine Wicker-Planquart; Isabelle Bally; Camilla De Nardis; Stéphane Dedieu; Anne Chouquet; Christine Gaboriaud; Nicole M Thielens; Jean-Philippe Kleman; Véronique Rossi
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.